Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer

doi:10.5306/wjco.v9.i8.172

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 8

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8077)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

445

WORD

172

HTML

4421

Tables (1-1)

531

Sum=5569

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1034

Download

1474

Sum=2508

Dec 20, 2018 (publication date) through Feb 23, 2026

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Editorial

World J Clin Oncol. Dec 20, 2018; 9(8): 172-179
Published online Dec 20, 2018. doi: 10.5306/wjco.v9.i8.172

Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer

Navid Sobhani, Daniele Generali, Fabrizio Zanconati, Marina Bortul, Bruna Scaggiante

Navid Sobhani, Daniele Generali, Fabrizio Zanconati, Marina Bortul, Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Academic Hospital, Trieste 34149, Italy

Bruna Scaggiante, Department of Life Sciences, University of Trieste, Trieste 34127, Italy

Author contributions: Sobhani N proposed and planned the topic of the editorial and wrote the first draft that has been revised and implemented by Generali D and Scaggiante B; Zanconati F and Bortul M further edited the manuscript.

Supported by Ricerca Sanitaria LILT 2015; and Beneficentia Foundation Stiftung, No. BEN2016/16 grants.

Conflict-of-interest statement: None.

Corresponding author to: Bruna Scaggiante, PhD, Professor, Department of Life Sciences, University of Trieste, Via Giorgeri, 1, Trieste 34127, Italy. bscaggiante@units.it

Telephone: +39-34-59700000

Received: July 13, 2018
Peer-review started: July 13, 2018
First decision: October 8, 2018
Revised: October 16, 2018
Accepted: November 26, 2018
Article in press: November 26, 2018
Published online: December 20, 2018
Processing time: 161 Days and 11.3 Hours

Core Tip

Core tip: The phosphatidylinositol 3-kinase-mammalian target of rapamycin (PI3K-mTOR) pathway sustains cancer progression and drug resistance. The first Food and Drug Administration approved molecule against this pathway was everolimus, an mTOR inhibitor, to be used in combination with exemestane in hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancers progressing to non-steroidal aromatase inhibitors. Drugs targeting other effectors such as PI3K, PI3Kα, Akt and mTORC1/2 have gained clinical interest. Nevertheless, everolimus remains the best option due to the relevant toxicity of the other drugs targeting the PI3K-mTOR pathway. Future directions point towards the development of biomarkers that would identify those patients who would benefit from the PI3K-mTOR inhibitors for improving overall survival.